3 Gene Therapy Stocks to Watch Amid Industry Turmoil

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of$75.06. The security is pacing for its worst single-day percentage loss since October 2023 after the gene-editing company revealed a 16-year-old boy died from acute liver failure after receiving its gene therapy for a rare muscular dystrophy. Year to date, the equity is down 37.5%. Beam Therapeutics Inc (NASDAQ:BEAM) is down 6.8% to trade at $22.85 at last glance, brushing off a price-targ ...